We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+11.93%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$208M
AUM Growth
+$13.7M
Cap. Flow
-$1.06M
Cap. Flow %
-0.51%
Top 10 Hldgs %
85.99%
Holding
26
New
2
Increased
2
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$7.37M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.82M
3
KALV
KalVista Pharmaceuticals
KALV
+$1.63M
4
OCRX
Ocera Therapeutics, Inc.
OCRX
+$302K

Top Sells

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$4.66M
2
ONC
BeOne Medicines Ltd
ONC
+$3.67M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$3.4M
4
LRMR icon
Larimar Therapeutics
LRMR
+$468K

Sector Composition

Rank Sector Weight
1 Healthcare 89.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$49.4M 23.71%
1,035,657
– –
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$2.36B
$38.4M 18.43%
6,071,142
+350,000
+6% +$1.82M
PDSB icon
3
PDS Biotechnology
PDSB
$41.1M
$24.2M 11.59%
96,679
– –
ASND icon
4
Ascendis Pharma A/S
ASND
$17.1B
$14.6M 7%
721,152
– –
BOLD
5
DELISTED
Audentes Therapeutics, Inc
BOLD
$8.25M 3.96%
458,882
– –
RARX
6
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$8.24M 3.95%
+542,500
New +$7.37M
CTMX icon
7
CytomX Therapeutics
CTMX
$788M
$6.35M 3.05%
577,831
– –
CLCD
8
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$5.79M 2.78%
159,110
– –
SIOX
9
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.34M 2.56%
53,699
– –
HRTX icon
10
Heron Therapeutics
HRTX
$89.1M
$5.32M 2.55%
405,901
– –
CHRS icon
11
Coherus Oncology
CHRS
$216M
$3.65M 1.75%
129,629
– –
STML
12
DELISTED
Stemline Therapeutics, Inc.
STML
$3.38M 1.62%
315,980
– –
ARCT icon
13
Arcturus Therapeutics
ARCT
$172M
$3.23M 1.55%
219,638
– –
ORKA
14
Oruka Therapeutics
ORKA
$5.59B
$3.08M 1.47%
4,995
– –
AKTX
15
Akari Therapeutics
AKTX
$19.3M
$2.6M 1.25%
462
– –
OCRX
16
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.56M 1.23%
1,217,872
+129,500
+12% +$302K
LPCN icon
17
Lipocine
LPCN
$18.4M
$1.55M 0.74%
24,706
– –
SYRE icon
18
Spyre Therapeutics
SYRE
$8.7B
$1.52M 0.73%
14,005
– –
KALV
19
DELISTED
KalVista Pharmaceuticals
KALV
$1.32M 0.63%
+221,651
New +$1.63M
ADVM
20
DELISTED
Adverum Biotechnologies
ADVM
$812K 0.39%
28,000
– –
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$195K 0.09%
3,270
– –
LRMR icon
22
Larimar Therapeutics
LRMR
$384M
– –
-11,790
Closed -$468K
RGNX icon
23
Regenxbio
RGNX
$511M
– –
-332,494
Closed -$4.66M
ONC
24
BeOne Medicines Ltd
ONC
$32.4B
– –
-119,000
Closed -$3.67M
ACHN
25
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-420,000
Closed -$3.4M

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q4 2016 Portfolio in Review

As of Q4 2016, VHCP Management II held 26 positions worth $208M, up 7% from $195M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

VHCP Management II's Q4 2016 filing shows 2 new, 2 increased and 4 closed positions. Its largest new stake was Ra Pharmaceuticals, Inc. Common Stock: 542,500 shares worth $8.24M. The largest sale was Regenxbio, an estimated $4.66M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier.

  • VHCP Management II's largest Q4 2016 buy was Ra Pharmaceuticals, Inc. Common Stock: 542,500 shares worth $8.24M.
  • VHCP Management II added most to BioCryst Pharmaceuticals in Q4 2016, an estimated $1.82M increase.
  • VHCP Management II fully exited Regenxbio in Q4 2016, selling an estimated $4.66M.
  • VHCP Management II's ten largest holdings make up 86% of its $208M portfolio in Q4 2016.
  • VHCP Management II opened 2 new positions and closed 4 in Q4 2016.
  • VHCP Management II's portfolio value rose 7% quarter-over-quarter to $208M.

Based on VHCP Management II's 13F filing for Q4 2016, filed 13 Feb 2017.